Next-gen bioinformatics tool enables big data analysis without programming expertise
A new data analysis tool developed by researchers at The University of Texas MD Anderson Cancer Center incorporates a user-friendly, natural-language interface to allow biomedical researchers without specialized expertise in bioinformatics or programming languages to conduct intuitive analysis of large datasets.
The open-access, artificial intelligence (AI)-driven program, called DrBioRight, was created to lower barriers for...
MD Anderson and Taiho Pharmaceutical announce collaboration to accelerate development of novel therapies for brain metastasis and other unmet medical needs
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration...
Monica Johnson receives Julie and Ben Rogers Award for Excellence
The University of Texas MD Anderson Cancer Center has awarded Monica Johnson, M.H.A., C.P.X.P., the Julie and Ben Rogers Award for Excellence...
KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial
ABSTRACT: 1257O
In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefits. Results from the trial were published today in the New England Journal of Medicine and data from the lung cancer cohort also were presented at the European Society for Medical Oncology (ESMO) Virtual Congress...
New study from MD Anderson and BridgeBio’s Navire Pharma shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc...
Combination immunotherapy benefits subset of patients with advanced prostate cancer
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab...
MD Anderson and Astex Pharmaceuticals announce strategic collaboration to accelerate clinical evaluation of therapies for patients with leukemia
The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co....
MD Anderson and Xencor enter strategic collaboration to advance investigational XmAb® drug candidates
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic collaboration to study investigational...